Importance of Pharmacovigilance in Clinical Trials: Key Safety Activities and Regulatory Requirements

Pharmacovigilance (PV) during clinical trials encompasses the science and activities related to the detection, assessment, understanding, and prevention of adverse events and other drug-related problems associated with investigational products. 

During clinical development, the safety profile of a new drug continues to evolve; therefore, systematic safety monitoring is essential to protect trial participants and ensure the reliability of clinical data. 

Pharmacovigilance activities begin with the first administration of an investigational product in humans and continue throughout all phases of development. Furthermore, clinical trials typically involve limited and selected populations, making continuous safety surveillance critical for the early identification of potential risks. 

In accordance with ethical principles such as the Declaration of Helsinki and Good Clinical Practice (GCP), safeguarding the rights, safety, and well-being of trial participants remains the foremost priority in clinical research.

Why Pharmacovigilance Is Critical in Clinical Trials

Pharmacovigilance is a fundamental component of clinical trials, as investigational products are evaluated in humans with an evolving safety profile. Key pharmacovigilance activities during clinical development include adverse event (AE) and serious adverse event (SAE) reporting, continuous safety monitoring, systematic data collection, regulatory reporting, and ongoing risk management.

Throughout the different phases of clinical trials, the potential for adverse events remains present. 

• Phase I trials typically involve a small number of healthy volunteers and primarily assess safety, tolerability, pharmacokinetics, and pharmacodynamics. 
• Phase II trials are conducted in patients with the target disease to further evaluate safety and preliminary efficacy in a relatively homogeneous population. 
• Phase III trials include larger and more diverse patient populations to confirm efficacy and further characterize the safety profile. 
• Phase IV studies continue to monitor long-term safety and effectiveness in real-world settings.

Before trial initiation, a detailed clinical trial protocol is developed by the sponsor in collaboration with the investigator, outlining study objectives, methodology, eligibility criteria, and safety monitoring procedures. 

In addition, informed consent is obtained from each participant before enrolment. During the trial, investigators and sponsor safety teams actively monitor, assess, and report adverse events to ensure participant protection and regulatory compliance. These pharmacovigilance activities are essential to identify potential risks early and to support the safe development of new medicinal products.

The likelihood of detecting rare adverse reactions increases as clinical development progresses and patient exposure expands.

Key Pharmacovigilance Activities During Clinical Trials

3.1 Adverse Event (AE) and Serious Adverse Event (SAE) Collection

Systematic collection of adverse events (AEs) and serious adverse events (SAEs) is a core pharmacovigilance activity during clinical trials.

•  Adverse Event: An AE is defined as any untoward medical occurrence in a clinical trial participant administered an investigational product, which does not necessarily have a causal relationship with the treatment. 
• Serious Adverse Event: An SAE is an adverse event that meets seriousness criteria such as death, life-threatening condition, hospitalization, disability, congenital anomaly, or other medically important condition as defined in ICH E2A.

Investigators are responsible for the  detection, documentation, and reporting of AEs and SAEs to the sponsor within protocol-specified timelines. The sponsor subsequently evaluates and reports relevant cases to regulatory authorities as required.

3.2 Medical Review and Causality Assessment

Following AE identification, medical review and causality assessment are performed to evaluate the likelihood of a relationship between the investigational product and the reported event. Causality assessment is typically conducted by the investigator and further reviewed by sponsor medical or pharmacovigilance experts using established assessment methods. This step is essential for identifying adverse drug reactions and supporting ongoing safety evaluation.

3.3 Expectedness Assessment

Expectedness assessment determines whether a suspected adverse reaction is consistent with the known safety profile of the investigational product as described in the Reference Safety Information (RSI), which is typically contained in the Investigator’s Brochure (IB) during clinical development or the Company Core Data Sheet (CCDS) for marketed products. Events that are not consistent with the RSI are classified as unexpected and may require expedited regulatory reporting, particularly if seriousness and causality criteria are also met.

3.4 SUSAR Identification and Expedited Reporting

A Suspected Unexpected Serious Adverse Reaction (SUSAR) is identified when an event is serious, suspected to be related to the investigational product, and unexpected based on the RSI. SUSARs require expedited reporting to regulatory authorities within defined timelines in accordance with ICH E2A and regional regulations. Timely identification and reporting of SUSARs are critical for regulatory oversight and participant protection.

3.5 Periodic Safety Review — Development Safety Update Report (DSUR)

In addition to expedited reporting, sponsors perform cumulative safety evaluation through the Development Safety Update Report (DSUR). The DSUR provides an annual, comprehensive assessment of the evolving safety profile of the investigational product during clinical development and supports ongoing benefit–risk evaluation.

4. Roles and Responsibilities in Clinical Trial Safety

4.1 Investigator Responsibilities

Investigators are responsible for the day-to-day safety oversight of trial participants. Their key responsibilities include:

• Continuous clinical monitoring of study participants throughout the trial
• Early detection and documentation of all adverse events (AEs) and serious adverse events (SAEs)
• Performing initial medical evaluation, including seriousness and causality assessment
• Providing appropriate medical care and follow-up for participants experiencing adverse events
• Reporting SAEs to the sponsor within protocol-defined timelines
• Maintaining accurate and complete safety records in source documents and case report forms
• Ensuring the rights, safety, and well-being of trial participants are protected

Through these activities, investigators serve as the frontline safeguard for participant safety during clinical trials.

4.2 Sponsor Responsibilities

The sponsor is responsible for establishing and maintaining the overall pharmacovigilance system during clinical development. Key sponsor responsibilities include:

• Maintaining and managing the clinical safety database
• Performing ongoing aggregate safety review and signal detection
• Reviewing reported AEs/SAEs from investigator sites
• Evaluating and expediting reporting of SUSARs to regulatory authorities and ethics committees
• Preparing and submitting the Development Safety Update Report (DSUR) annually
• Periodically reviewing and updating the Reference Safety Information (RSI) as new data emerge
• Ensuring global regulatory compliance for clinical trial safety reporting
• Continuously monitoring the benefit–risk profile of the investigational product

Through systematic safety surveillance and regulatory reporting, the sponsor ensures robust oversight of the investigational product’s safety profile.

6. Regulatory Framework Supporting Pharmacovigilance in Clinical Trials

Pharmacovigilance activities in clinical trials are governed by internationally harmonized regulatory guidelines that ensure consistent safety monitoring and reporting. 

• Good Clinical Practice (ICH E6) outlines the responsibilities of investigators and sponsors in protecting trial participants and maintaining data integrity.
•  ICH E2A provides the framework for clinical safety data management, including definitions and expedited reporting requirements for serious and unexpected adverse reactions.
•  In addition, ICH E2F describes the preparation of the Development Safety Update Report (DSUR) for periodic safety evaluation during clinical development. 
• Regulatory authorities such as the FDA and EMA further enforce these requirements to ensure robust safety oversight throughout the lifecycle of an investigational product.

7. Practical Example (Mini Case)

This is a hypothetical example for educational purposes.

Study Phase: Phase II clinical trial
Subject: Adult trial participant
Suspect Product: Investigational medicinal product

Event Description:

• Elevated liver enzymes observed during routine monitoring
• Participant required hospitalization

Seriousness Assessment:

• Met seriousness criteria (hospitalization)

Causality Assessment:

• Assessed by the investigator as related to the investigational product

Expectedness Assessment:

• Event not listed in the Reference Safety Information (RSI)

• Classified as unexpected

Regulatory Classification:

• Case identified as a Suspected Unexpected Serious Adverse Reaction (SUSAR)

Action Taken:

• Sponsor submitted expedited report to regulatory authorities within required timelines
• Enhanced safety monitoring implemented for ongoing study participants

Learning Point:

This case demonstrates the importance of timely detection, assessment, and reporting of serious unexpected reactions to ensure participant safety during clinical development. 

8. Conclusion:

Pharmacovigilance is an essential component of clinical trials, ensuring continuous evaluation of the safety profile of investigational products throughout clinical development. As clinical trial designs evolve and incorporate diverse data sources, the importance of proactive, systematic safety monitoring continues to grow. Effective collaboration between investigators and sponsors enables timely detection, assessment, and reporting of adverse events, thereby safeguarding trial participants. Robust pharmacovigilance practices not only support regulatory compliance but also contribute to informed benefit–risk evaluation and the successful development of safe and effective medicinal products.

Frequently Asked Questions (FAQ)

Q1. What is the role of pharmacovigilance in clinical trials?

Pharmacovigilance in clinical trials focuses on the systematic detection, assessment, and reporting of adverse events associated with investigational products. It ensures continuous clinical trial safety monitoring, protects trial participants, and supports ongoing benefit–risk evaluation throughout clinical development.

Q2. What is a SUSAR in clinical research?

A Suspected Unexpected Serious Adverse Reaction (SUSAR) is an adverse reaction that is serious, considered related to the investigational product, and unexpected based on the Reference Safety Information (RSI). SUSARs require expedited reporting to regulatory authorities within defined timelines.

Q3. Who reports serious adverse events (SAEs) in clinical trials?

In clinical trials, investigators are responsible for promptly detecting and reporting serious adverse events (SAEs) to the sponsor according to protocol timelines. The sponsor then evaluates the case and submits required regulatory reports, including SUSAR reports when applicable.

Q4. Why is pharmacovigilance important during clinical development?

Pharmacovigilance is critical during clinical development because the safety profile of an investigational product is still evolving. Continuous safety monitoring helps identify potential risks early, supports regulatory compliance, and ensures the protection of trial participants.